Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Half a sleep this morning, I saw the news icon next to ATOM and got a little excited.......until I clicked on it....ugh.
kt
And yet we're are at new lows again! Never thought I would see $2's this late in the game! 😔
kt
Added some commons at $3.
kt
I bought some of those calls myself today.....we need therapy lol!
kt
Let’s hope so. Stock price has sure taken a beating these last few months!
.0054 X .0066....most of the pennies are dead. Luckily this is the only one I'm stuck in....tax write off I guess. 😟
Yeah I was a little off lol. Have to double check figures before posting. Here are the current market caps. AMZN 1.9 Trillion and at $1 SPZI MC would be 5.8 billion not trillion. Hate when people do that and I apologize.
https://www.otcmarkets.com/stock/AMZN/security
https://www.otcmarkets.com/stock/SPZI/security
kt
Added some on this volume surge. Have no clue but gets my average down to a better number lol.
Added at $4 this morning and just figured out it brought my average down to $6.66..... Well that's not good! 😒
And MRES sitting at a 52w low. :(
Looks like another one of Charlie's fantasy tales. Nobody I know received this letter. I would love to hear if anyone ever received this either in the mail or email. I'm betting it's just something Charlie typed up to delay the heat for a while until the next "merger". Would love to be proven wrong!
kt
I don't know how long you've been here but I'm still pretty pissed about WUHN. I originally invested here because of Jeff and that's been a few years ago. I'm patient but this is starting to test it. I'll give it to the end of year and then it's a write off.
kt
Yet the stock is stuck in molasses.
Very interested to see what they do to address the GaN market.
So, the GaN market is very interesting. Actually, this whole compound semiconductor, it’s an area that we have been doing research on for a few years. So, although this is our first announcement, it isn’t something we just started thinking about. So, there is multiple ways that our business model can be used for GaN. We can just license our MST technology, just like we do today with regular semiconductor makers to adopt MST on wafers and then build GaN wafers on top of that. That’s one way that we could do it. We will probably license our GaN technology separately from the rest of our licensed technology because it may have very high value. The second thing we could do is maybe we could become a manufacturer of GaN wafers at least in modest volumes, and that would allow us to generate revenue. And if it was a very high-value technology, maybe we could make a very nice-looking gross margin there and help to subsidize the rest of our business. We don’t have a decision to do that yet. I mean we have a very strong philosophy about making a business model that’s got a lot of leverage to the bottom line. And so, if we were to become a manufacturer, obviously, we would have to have a lot more CapEx, which might not work well with that. But we could do something on the smaller volume manufacturing side. And – but I think for our customers who would go into high-volume manufacturing, it’s most likely that we have licensed directly to them. So, we have been looking at the GaN market for a while. We have had a lot of marketing studies going on about how to approach it, but we haven’t got a final determination about what we do. I can tell you, I think it’s a – it would be a much faster time to market. And I am pretty excited about the prospects of MST there and the prospects in a few other areas in the compound semiconductor market.
Compound semiconductor materials have traditionally been difficult to manufacture due to crystal defects, some of which can be caused by a mismatch with nonnative substrates. The mismatch creates stresses at the interface, which propagate through the wafer causing cracks and other defects that have limited both the size and the yield of wafers, making economical manufacturing difficult. Atomera’s MST film can relax or de-strain the interface between two different crystal latices, and we’ve been filing a number of patents over the years related to this effect. Recently, we began working with one of the world’s leading authorities in compound semiconductor fabrication, Professor Edwin Pinar at Texas State University to investigate how MST could help solve this whole manufacturing problem.
A material which can significantly improve the quality of GaN wafers and potentially enable them to be manufactured at a larger size is a game changer that the industry is currently seeking. Early experiments growing GaN wafers using MST have shown very promising results. While we still have work to do, if our current trajectory continues, we should be able to enter the market and generate revenue much more quickly than in our traditional engagements with semiconductor customers, potentially even before the end of this year.
This could be pretty big imo.
kt
Thanks for posting.
You actually still believe a word that comes out of Scott’s mouth? He’s done nothing but lie to shareholders for years! I’m still waiting on audited financials lol.
Agree. The only penny I’m holding at the moment. Still very early here. The story is just starting.
kt
Starting to trade a little better lately.
Wish they would have spelled it out a little better and given a date. Guess we'll see??
kt
I think this is the link you wanted to post:
https://www.accesswire.com/838150/mres-m2bio-sciences-provides-corporate-update
If all preferred shares are converted into common shares, MRES is projected to hold approximately 71% of RLAB's fully diluted shares, with an expected total of 56,368,000 outstanding shares. As a result, investors can gain exposure to RLAB either directly or by holding shares in MRES.
So MRES holders would have around 40m shares of RLAB. So about 1 share for every 60 shares of MRES? That's just based on OS of 2,371,424,113 divided by 40 million is around 60.
Just off the top of my head......buying 100k of MRES here at .0085($850) gets you 1,666 shares of RLAB trading at .20($333).
kt
Heaven help them if they’re thinking like me lol.
Time will tell but low 6’s seem like a good deal to me. Just adding to my pile.
Added a bunch today. Maybe I’m just a glutton for punishment lol.
Transcript of the earnings call:
https://www.fool.com/earnings/call-transcripts/2024/02/13/atomera-atom-q4-2023-earnings-call-transcript/
kt
LOS GATOS, CA / ACCESSWIRE / February 13, 2024 / Atomera Incorporated (NASDAQ:ATOM), a semiconductor materials and technology licensing company, today provided a corporate update and announced financial results for the fourth quarter and fiscal year ended December 31, 2023.
Recent Company Highlights
Achieved revenue from commercial licensee for two milestones
Second customer completed installation of MST technology
Executed an MSTcad license with a large semiconductor manufacturer
Management Commentary
"There is clear evidence the company is executing on its strategy to commercialize MST. With our technology now installed at two customer fabs, we're focusing on moving additional customers along the engagement pipeline toward the royalty phase," said Scott Bibaud, President and CEO. "The semiconductor industry is currently in an ideal state to adopt new technology and the performance improvements enabled by MST are compelling to fabs and foundries seeking to gain cost-effective advantages in highly competitive markets."
Financial Results
Revenue for the fourth quarter of 2023 was $550,000. The Company incurred a net loss of ($4.6) million, or ($0.18) per basic and diluted share in the fourth quarter of 2023, compared to a net loss of ($4.3) million, or ($0.18) per basic and diluted share, for the fourth quarter of 2022. Adjusted EBITDA (a non-GAAP financial measure) in the fourth quarter of 2023 was a loss of ($3.8) million compared to an adjusted EBITDA loss of ($3.5) million in the fourth quarter of 2022.
For fiscal year 2023, revenue was $550,000, compared with $382,000 in fiscal 2022. Net loss was ($19.8) million, or ($0.80) per basic and diluted share for fiscal 2023, compared to ($17.4) million, or ($0.75) per basic and diluted share in fiscal 2022. Adjusted EBITDA for fiscal 2023 was a loss of ($16.6) million compared to an adjusted EBITDA loss of ($14.1) million in fiscal 2022.
The Company had $19.5 million in cash, cash equivalents and short-term investments as of December 31, 2023, compared to $21.2 million as of December 31, 2022.
The total number of shares outstanding was 26.1 million as of December 31, 2023.
Fourth Quarter and Fiscal Year 2023 Results Webinar
Atomera will host a live video webinar today to discuss its financial results and recent progress.
Date: Tuesday, Feb. 13, 2024
Time: 2:00 p.m. PT (5:00 p.m. ET)
Webcast: Accessible at https://ir.atomera.com
Note about Non-GAAP Financial Measures
In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP, in this press release, Atomera presents adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is determined by taking net loss and eliminating the impacts of interest, depreciation, amortization and stock-based compensation. Our definition of adjusted EBITDA may not be comparable to the definitions of similarly-titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of our reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management. A table reconciling this measure to the comparable GAAP measure is available in the accompanying financial tables below.
About Atomera Incorporated
Atomera Incorporated is a semiconductor materials and technology licensing company focused on deploying its proprietary, silicon-proven technology into the semiconductor industry. Atomera has developed Mears Silicon TechnologyTM (MST®), which increases performance and power efficiency in semiconductor transistors. MST can be implemented using equipment already deployed in semiconductor manufacturing facilities and is complementary to other nano-scaling technologies already in the semiconductor industry roadmap. More information can be found at www.atomera.com.
https://finance.yahoo.com/news/atomera-provides-fourth-quarter-fiscal-210100298.html
https://ir.atomera.com/download/companies/270138a/Presentations/Q423%20Update%20Call%20deck%20FINAL.pdf
ARM up another 40% today. Wow.
kt
Maybe 2 spinoffs this year?? 👍️
kt
MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward
Press Release | 02/09/2024
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 9, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to announce the following updates for its M2Biome division:
The M2Biome division relates to all nutrition aspects of M2Bio Sciences and associated education. Increasing evidence exists to elucidate the link between the gut and all things health and how important it is to optimize the microbiome through lifestyle. M2Biome provides evidence-based products that meet the specific needs of various individual profiles, are of the highest quality, and are environmentally sustainable. We are committed to continuous innovation, striving to provide cutting-edge solutions for healthier living. M2Biome also supports M2Bio Food & Beverage in research and development, ensuring that only evidence-based, high-quality products come to market.
2023 was undoubtedly a year of growth, where the division went from just a concept to launching the website, providing ‘bite-sized' nutritional information in the form of topical articles, providing a plethora of science-backed recipes, and going full-steam ahead with educational content on various social media platforms.
Our website (found here) provides information for healthcare professionals and consumers alike. Key features include the diabetes risk screening tool, educational content, and a range of recipes that often incorporate products from M2Bio Science's consumer-facing brands Liviana and Medspresso. In terms of research and article-writing, some of the topics our team explored included the intricate links between diet and Alzheimer's Disease, why weight loss shouldn't be a ‘blanket approach' to those with overweight and obesity, the role of the endocannabinoid system in health, as well as some practical tips on how to pack a nutritious lunch box. Our mission to provide bite-sized information will continue into 2024 when we will delve further into gut health and its implications for the rest of the body.
We are building and fostering a robust online community around health and wellness through social media. In 2024, we will ensure more evidence-based information, including summaries of relevant, newly published studies.
As always, a pragmatic take-home message will be supplied from the learnings.
2023 was filled with recipe writing, using science to elevate the health of meals. This entails a continuous learning curve for the sweet spot between taste, health, convenience, sustainability, affordability, and practicality. We explore alternative, often overlooked healthy ingredients and find ways to incorporate them practically into dishes. In these recipes, we lean on cooking methods to bring out the best in ingredients and focus on locally available seasonal produce. Making minor adjustments to meals and snacks adds to a ‘healthy whole.' Wilna Eksteen, our in-house Dietitian and Cardiometabolic Product Developer, will continue to be innovative in this space and provide mouth-watering recipes that satisfy many aspects of one's health. Furthermore, we will be working on producing an elegant recipe book. This recipe book will blend a traditional approach with technology, providing an interactive end-product set apart from your average recipe book.
M2Biome supported the development of several products under Liviana. Notably, the premium black garlic in extra virgin olive oil, as well as the luxurious chocolate range, to be launched in 2024. Under M2Biome, we also worked on researching and developing several drinks that will address metabolic, gut, and cognitive health. Not only will they meet specific health needs, but we guarantee they will be delicious - allowing a seamless integration into one's daily routine. We are developing nutritional bars as a wholesome alternative to existing market options. We aim to minimize the ingredient list while maximizing consumer fiber and micronutrient intake contributions.
In line with a personalized approach to nutrition, M2Biome is incorporating Artificial Intelligence and Machine Learning for better patient outcomes. Machine learning takes enormous data to uncover patterns and insights related to dietary choices, health outcomes, and nutritional needs. Leveraging machine learning algorithms assists with developing personalized nutrition recommendations based on individual factors such as age, gender, activity level, and health conditions, leading to more tailored and effective dietary interventions.
The development of the M2Biome App will be a significant focus in 2024. We have secured our partner, based in Singapore, to assist in developing the app. Significant strides have already been made, and we expect to launch the first iteration in 2024. This app will be a game changer in the health industry and benefit consumers and healthcare providers. The next generation of healthcare is here-personalized precision medicine driven by advanced artificial intelligence technologies.
"As the Managing Director of M2Biome, I am proud of our remarkable journey through 2023, where we built a solid foundation for what will come from this division. Our dedicated team has tirelessly worked towards this goal because we are committed to transforming the nutrition space regarding health and wellness. While 2023 saw some great progress, we eagerly anticipate the exciting prospects awaiting us in 2024. The upcoming year promises groundbreaking advancements, innovative partnerships, and an unwavering dedication to improving the nutritional landscape for all." said Nicola Royce.
"We recognize the critical need for an application that doesn't just offer nutritional guidance but truly revolutionizes it. Our M2Biome app stands leagues beyond the traditional offerings in the current market. With the integration of AI-driven, state-of-the-art mobile software and hardware technologies, we're not just setting a new standard in personalized nutrition; we're redefining it. This innovative leap is a testament to our commitment to merging advanced technology with health and wellness, offering unmatched accuracy and customization in dietary planning. This app is set to become an industry juggernaut, the dominant force in its field." - Jeff Robinson, CEO, M2Bio Sciences.
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."
Publicly traded Company (OTC Pink:MRES)
https://www.otcmarkets.com/stock/MRES/news/MRES-M2Biome-2023-Year-End-Review-and-2024-Looking-Forward?id=429995
I would be happy with 2 cents lol.
Agree. Right now it's the only penny I feel comfortable holding overnight.
kt
Will be interesting to see the ratio of shares MRES holders receive. One of many spinoffs that are coming in here.
kt
Real American Announces Acquisition of M2MMA from MRES
Press Release | 01/30/2024
PALM SPRINGS, CA / ACCESSWIRE / January 30, 2024 / The Real American Capital Corporation (OTC PINK:RLAB) is pleased to announce the acquisition from Institute of Biomedical Research Corporation (OTC PINK:MRES) 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish a mixed martial arts league and are herein referred to as "M2MMA" (https://m2mma.com).
The transaction will be settled entirely in shares, resulting in a change of control of Real American Capital Corporation.
It was previously announced that Jeff Robinson and Willem Jonker, CEO and CFO of MRES, respectively, have been appointed Chairman and Chief Financial Officer of RLAB.
Doug Newton, outgoing co-CEO of RLAB and a black belt holder, has a lifelong connection to martial arts and the world of professional sports. "M2MMA is just the right business for the Company, especially with the exciting innovations Jeff and his team are bringing to the sport", he says.
"The M2MMA concept, which will revolutionize mixed martial arts, was incubated inside MRES over the past months and is now ready to be spun out and stand on its own feet. You can expect many more details to be revealed very soon", says Jeff Robinson.
About Real American Capital Corp. (OTC PINK: RLAB):
Real American Capital Corporation (OTC PINK: RLAB) trades on the Pink Open Market. Investors can find Real-Time quotes and market information for the company at https://www.otcmarkets.com/stock/RLAB/.
RLAB's menu of US trademarks registered or applied for includes Resurgent®; Nature Treating Nature®; Born & Bred in the USA® (owned by RLAB since 2011); Rising Harvest; and Healthy Living Soil ®.
https://www.otcmarkets.com/stock/MRES/news/Real-American-Announces-Acquisition-of-M2MMA-from-MRES?id=428814
This one has held up really well.....really small float, less than 4m held at DTC.
https://www.otcmarkets.com/stock/RLAB/security
Every time it gets some decent buys, sellers put a clamp on it. Been like this for a few months now. Hopefully we hear something about their connection to RLAB this week. A spinoff would get some eyes here.
kt
.37 HOD after dipping to under .23 earlier....very strong.
kt
There's a few of them floating around here at Ihub. Pretty sad existence imo but social media is full of them these days.
kt
Picked up some .008's....don't really know if I want them but grabbed a few on this late Friday selloff.
https://www.otcmarkets.com/filing/html?id=17210752&guid=n9d-k6ImV7eHJth
NOTICE IS HEREBY GIVEN that the following action has been approved pursuant to the written consent of the holders of a majority of the voting power of the outstanding common stock of Kat Exploration, Inc., a Nevada corporation (the “ Company ,” “ we ,” “ us ,” or “our”) dated January 9, 2024, in lieu of a special meeting of the stockholders and in accordance with Nevada Revised Statutes 78.320:
A. To effect a reverse split of the Company’s common stock on the basis of 679 (Six Hundred Seventy Nine) common shares for 1 (One) new common share.
B. To amend the Company’s Articles of Incorporation, to change the number of authorized shares of common stock of the Company to 2,000,000,000, $0.0001 par value, following the reverse split.
C. To amend the Company’s Articles of Incorporation to change the Company’s name to Golkor Inc.
Was just reading....thanks!